These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 30166271)
1. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271 [TBL] [Abstract][Full Text] [Related]
2. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208 [TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702 [TBL] [Abstract][Full Text] [Related]
5. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841 [No Abstract] [Full Text] [Related]
7. A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis. Zhang H; Zhu M; Shan X; Zhou X; Wang T; Zhang J; Tao J; Cheng W; Chen G; Li J; Liu P; Wang Q; Zhu W Gene; 2019 Mar; 687():246-254. PubMed ID: 30458288 [TBL] [Abstract][Full Text] [Related]
8. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. Hur K; Toiyama Y; Schetter AJ; Okugawa Y; Harris CC; Boland CR; Goel A J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663689 [TBL] [Abstract][Full Text] [Related]
9. Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Li J; Liu Y; Wang C; Deng T; Liang H; Wang Y; Huang D; Fan Q; Wang X; Ning T; Liu R; Zhang CY; Zen K; Chen X; Ba Y Sci Rep; 2015 Aug; 5():12921. PubMed ID: 26250939 [TBL] [Abstract][Full Text] [Related]
10. Novel Multiple miRNA-Based Signatures for Predicting Overall Survival and Recurrence-Free Survival of Colorectal Cancer Patients. Qian J; Zeng L; Jiang X; Zhang Z; Luo X Med Sci Monit; 2019 Sep; 25():7258-7271. PubMed ID: 31560680 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a hypoxia-related microRNA signature in patients with colorectal cancer. Yang Y; Qu A; Wu Q; Zhang X; Wang L; Li C; Dong Z; Du L; Wang C Aging (Albany NY); 2020 Jan; 12(1):35-52. PubMed ID: 31926112 [TBL] [Abstract][Full Text] [Related]
15. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954 [TBL] [Abstract][Full Text] [Related]
17. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750 [TBL] [Abstract][Full Text] [Related]
18. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692 [TBL] [Abstract][Full Text] [Related]
19. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Yuan D; Li K; Zhu K; Yan R; Dang C Cancer Biol Ther; 2015; 16(2):268-75. PubMed ID: 25629978 [TBL] [Abstract][Full Text] [Related]
20. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]